다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

PLRZ

Polyrizon (PLRZ)

Polyrizon Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:PLRZ

일자	시간	출처	헤드라인	심볼	기업
2025/03/19	20:35	GlobeNewswire Inc.	Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/19	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/14	21:38	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/14	21:35	GlobeNewswire Inc.	Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/14	05:42	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/13	20:51	GlobeNewswire Inc.	Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/12	05:27	GlobeNewswire Inc.	Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/12	05:23	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/12	05:05	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/11	06:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/10	20:47	GlobeNewswire Inc.	Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform	NASDAQ:PLRZ	Polyrizon Ltd
2025/03/06	06:00	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:PLRZ	Polyrizon Ltd
2025/01/30	20:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2025/01/30	19:55	GlobeNewswire Inc.	Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform	NASDAQ:PLRZ	Polyrizon Ltd
2025/01/23	22:59	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2025/01/23	20:40	GlobeNewswire Inc.	Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial	NASDAQ:PLRZ	Polyrizon Ltd
2025/01/23	06:15	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:PLRZ	Polyrizon Ltd
2025/01/22	06:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2025/01/16	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PLRZ	Polyrizon Ltd
2025/01/11	06:16	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/31	06:52	Edgar (US Regulatory)	Form F-1 - Registration statement for certain foreign private issuers	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/30	20:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/30	20:25	GlobeNewswire Inc.	Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/19	22:21	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/19	21:22	GlobeNewswire Inc.	Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/18	20:25	GlobeNewswire Inc.	Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/14	06:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/13	20:25	GlobeNewswire Inc.	Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/03	06:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PLRZ	Polyrizon Ltd
2024/12/02	22:02	GlobeNewswire Inc.	Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial	NASDAQ:PLRZ	Polyrizon Ltd

검색 관련기사 보기:NASDAQ:PLRZ

Marriott Vacations World...

L&G ESG EMG MKT GV BD 0-...

DAXglobal Nuclear Energy...

MSCI World Information T...

Teucrium Agricultural

S&P ASX 200 A REIT OPIC

DAXsubsector Industrial ...

Centerpoint Energy

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관